TAK-227
Phase 2- Indications
- Celiac disease
Company intelligence / Profile preview
Pharma-Zentrale
Herdecke, Nordrhein-Westfalen, Germanypharma-zentrale.de ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 2
01
Overview
Pharma-Zentrale produces commercial-stage probiotic drugs and phytopharmaceuticals, including the well-known products Mutaflor (E. coli Nissle 1917), Yomogi (Saccharomyces boulardii), and Adiclair (nystatin). Clinical use is established, with multiple products marketed for gastrointestinal and infectious diseases[1][3][4].
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Live biotherapeutic product therapyProbioticPhytopharmaceuticalSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Pharma-Zentrale.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharma-Zentrale.